2015 is to be a very important year: the statistics has reported that the patents of best-selling biological drugs after 2011 will gradually expire and the market value is estimated to reach USD160 billion, wherein there is Sanofi Lantus and Amgen Neulasta, etc. Constantly ranking in the forefront in sales for many years. As a result, potential opportunities of biosimilars in 2015 may peak.
But according to some persons, the launch progress of biosimilars in the market may be very slow and there are differences inside FDA during the examination, therefore, it may take 10 years to achieve a relatively smooth process. In the aspect of clinical use, many doctors are still skeptical about the safety and effectiveness of biosimilars and many relevant personnel are still vague about the concept of biosimilars. Only time can prove if the real situation of the future biosimilar market is really as beautiful as reflected by the predicted data.
